AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02185469 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser
Description: intraoperative laser retinopexy
Study NCT01466166 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pegloticase
Description: Pegloticase 8 mg intravenous every 2 weeks
Study NCT03965169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone spinal surgery
Description: spinal surgery in prone position under general anesthesia
Study NCT02537457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939)
Description: Rivaroxaban granule15mg for one day
Study NCT02537457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban (Xarelto, BAY 59-7939)
Description: Rivaroxaban tablet15mg for one day
Study NCT00575159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: investigational drug
Study NCT00575159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator
Study NCT01232725 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Donor Human Milk
Description: Donor Human Milk, obtained from the Mother's Milk of Iowa, a HMBANA milk bank
Study NCT02584985 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ETAP
Description: Primary transanal endoscopic approach, secondary transabdominal laparoscopic approach
Study NCT02584985 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Transabdominal Laparoscopic Proctectomy
Description: Primary transabdominal laparoscopic approach
Study NCT04673838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neurodevelopmental therapy
Description: Considering the individual needs and wishes of the patient, an exercise program will be created for each patient in accordance with their functional levels and supporting active participation of the person. The treatment program tailored to the patient; It will include weight transfer to the affected side in different positions, functional reaching out activities, stepping forward and walking activities.
Study NCT04673838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neurodevelopmental therapy
Description: Considering the individual needs and wishes of the patient, an exercise program will be created for each patient in accordance with their functional levels and supporting active participation of the person. The treatment program tailored to the patient; It will include weight transfer to the affected side in different positions, functional reaching out activities, stepping forward and walking activities.
Study NCT04673838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower extremity sensory training
Description: Lower extremity sensory training will only be applied to the Intervention Group for 4 weeks, 3 days a week and 12 sessions in total. In the lower extremity, 3 sets of soft tissue needing, stroking and fascia stretching will be applied on 5 areas as Quadriceps, Hamstring, Gastrosoleus Group, Peroneal muscles, ankle and foot. In addition, sensory stimulation will be applied in the same five regions of the lower extremity with 3 repetitions and 3 sets with a knurled ball, brush and sponge. Lower extremity mobilizations of PANat Therapy approach will be used with traction and gliding applications in all joints in the ankle and foot. Finally, intrinsic muscle stimulation will be performed for 3 minutes with a bottle and towel under the sole of the foot.
Study NCT01722006 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pairing condition
Study NCT01722006 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pairing condition
Description: 20 mg methamphetamine or placebo on four 4-hour laboratory sessions
Study NCT04194931 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous BCMA CAR-T cells and CD19 CAR-T cells
Description: Autologous BCMA CAR-T cells and CD19 CAR-T cells with average 1-5\*10\^6 cells/kg body weight,separately.
Study NCT04199741 — intervention group
Intervention type: DRUG
Intervention: 89Zr-DFO-SC16.56
Description: Injection of 2 mCi of 89Zr-DFO-SC16.56 for Phase I participants. Dose for Phase II will be determined by results from Phase I.
Study NCT04199741 — intervention group
Intervention type: DRUG
Intervention: SC16.56, Phase I, Cohort 2
Description: 7.5mg
Study NCT00235313 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: nicotine patch
Description: normal following with a nicotine patch
Study NCT04199741 — intervention group
Intervention type: DRUG
Intervention: SC16.56, Phase I, Cohort 3
Description: 22.5mg
Study NCT04199741 — intervention group
Intervention type: DRUG
Intervention: SC16.56, Phase II
Description: Dose for Phase II will be determined by results from Phase I.
Study NCT03975075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychophysiological monitoring
Description: 30 minutes of one channel (ECG) physiological monitoring with Mindfield eSense Pulse.
Study NCT03975075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychophysiological monitoring
Description: 30 minutes of one channel (ECG) physiological monitoring with Mindfield eSense Pulse.
Study NCT01315574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost
Description: One drop Travatan Z (0.004% ophthalmic solution) in affected eye once daily.
Study NCT01315574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: One drop Xalatan (0.005% ophthalmic solution) in affected eye once daily.
Study NCT01844076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinacrine and Capecitabine
Description: The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
Study NCT03975075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback training
Description: Traditional resonance frequency training with the Mindfield eSense Pulse smartphone application. Using visual feedback of real time parameters of HRV and the use of controlled breathing, participants are trained to reach a relaxed state.
Study NCT04544267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine, high-dose
Description: Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
Study NCT03617198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4 CAR+CCR5 ZFN T-cells
Description: A dual cohort, open-label, randomized study of the safety and tolerability of a single infusion of autologous T cells genetically modified to express a CD4 chimeric antigen receptor while also having zinc finger nuclease-mediated disruption of the CCR5 gene
Study NCT04544267 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent influenza vaccine, standard dose
Description: Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
Study NCT01773473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Mix25
Description: Administered SC
Study NCT01773473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Mix50
Description: Administered SC
Study NCT03884634 — intervention group
Intervention type: DEVICE
Intervention: Dabir Micropressure Overlay
Description: The study intervention is the use of the Dabir micropressure overlay on the operating room table during surgical operations. The device is positioned on top of a standard foam pad and gel heat exchanger. The overlay is already in use in some (but not all) adult cardiac operating rooms.~The overlay will be present on the operating room table for all adult cardiac operations. On odd calendar dates the device will be powered on, and on even calendar dates the device will be powered off.
Study NCT00644579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bLAC
Description: bLAC high and low dose and placebo
Study NCT00644579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02195830 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound of the inferior vena cava
Description: B mode ultrasound of the inferior vena cava Measurements taken 2cm from the hepatic vein IVC junction or 3cm from the right atrium IVC junction
Study NCT01708226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Modification Program
Description: Computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief.
Study NCT05069779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Oral administration of 10 mg of diazepam
Study NCT05069779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diazepam
Description: Oral administration of 10 mg of diazepam
Study NCT04002687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV-PG 1000-400 mg + AQ 612 mg
Description: The dosing will be carried out by an unblinded member of the investigator's staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. ATV-PG (or placebo) will always be given first, then AQ (or placebo).
Study NCT04002687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV-PG 1000-400 mg + AQ 612 mg
Description: The dosing will be carried out by an unblinded member of the investigator's staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. ATV-PG (or placebo) will always be given first, then AQ (or placebo).
Study NCT03136627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Tivozanib (AV-951): Phase 1b study and Phase 2a study: Subjects will receive 1 dose of tivozanib daily for 21 days followed by a 7 day rest period (1 cycle = 4 weeks).
Study NCT04002687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATV-PG 1000-400 mg + AQ 612 mg
Description: The dosing will be carried out by an unblinded member of the investigator's staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. ATV-PG (or placebo) will always be given first, then AQ (or placebo).
Study NCT01400828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: 20 mg (encapsulated) tablets QD/14 days
Study NCT03136627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab: Phase 1b study and Phase 2a study: All subjects will receive IV nivolumab 240 mg every 2 weeks administered over 1 hour.
Study NCT02143245 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Synovial Biopsy
Description: Synovial biopsy is a procedure using a guided needle, where 6 to 8 small tissue samples with be extracted from the shoulder using an x-ray guided needle.
Study NCT01400828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: 5 mg (encapsulated) tablets QD/14 days
Study NCT01400828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (encapsulated) Tablets QD/14 days
Study NCT03792711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure® Plus Advance
Description: Previous studies suggest that protein supplementation is an effective dietary strategy to decrease frailty by positively influence the weight loss or sarcopenia in elderly.~Lean body mass includes all body tissue except fat and is well recognized to be associated with an increased risk of morbidity and mortality. Oral nutrition supplements have been shown to increase food intake and body weight, but not lean body mass. In previous studies, β-hydroxy-β-methylbutyrate, which is leucine metabolite, has been shown to enhance protein synthesis and decrease protein degradation leading to increase lean body mass. It showed that β-hydroxy-β-methylbutyrate supplement with exercise increased lean body mass in health elderly population and improved the physical performance in elderly women.
Study NCT01945892 — intervention group
Intervention type: DRUG
Intervention: Ozurdex
Description: - Consent agreement - Patients should be informed that it is possible to get an active medication (Ozurdex implant) as an on label indication from the health insurance company if the diagnosis is accepted as an intraocular inflammation form of Uveitis posterior.
Study NCT04029337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Mitral Valve Replacement
Description: Minimally invasive transcatheter mitral valve implantation using the HighLife™ TMVR system
Study NCT00982605 — intervention group
Intervention type: PROCEDURE
Intervention: EBUS_TBNA
Description: EBUS during bronchoscopy
Study NCT00827489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTC-867
Study NCT00827489 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01241786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: Lenalidomide PO daily Day 1-21. For patients with baseline calculated creatinine clearance ≥ 30 ml/min and \< 60 ml/min the starting dose is 5 mg every other day (odd numbered days during Days 1-21). For patients with baseline calculated creatinine clearance ≥ 60 ml/min the starting dose is 5 mg daily on Days 1-21).
Study NCT01241786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75 mg/m2 IV or SC D 1-5
Study NCT02750410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered subcutaneously (SC)
Study NCT02750410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dulaglutide
Description: Administered subcutaneously (SC)
Study NCT02750410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT00940706 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TreadMill
Description: Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes~TreadMill training: During each session the subject will first exercise with basic stretching and muscle strengthening and then walk on the treadmill. According to the subject's rate of improvement, a therapist will determine the rate of increase in the velocity and slope. The treating therapist will make a written report after each session.
Study NCT00940706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity in groups
Description: Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes.~Activity Focus Training: this involves performing gross motor activities at exercise stations that involve repetitive, reciprocal and coordinated movements to facilitate strength and endurance conducted by physical therapists and instructing parents or other caregivers to be involved in the program. These activities are performed in a group, having a minimum of 6 children at one time.
Study NCT00940706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitoring physical activity
Description: Activity monitoring with accelerometers
Study NCT03950323 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI with Facial nerve tractography
Description: MRI with Facial nerve tractography in addition to T1 imaging, T1 gadolinium imaging and T2 imaging.
Study NCT05780281 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIR-7831
Description: VIR-7831 is a fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibody (mAb) derived from antibody S309 from a survivor of SARS-CoV-1.
Study NCT05780281 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% sodium chloride solution
Study NCT05780281 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Antiviral agent
Study NCT05780281 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Antiviral agent
Study NCT00378729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and FSHr
Description: treatment for infertility
Study NCT00378729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovarian drilling by FERTILOSCOPY
Description: surgical ovarian drilling
Study NCT02957708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mCIMT + SR
Description: Each participant wears a customized cotton sling on the unaffected arm for six hours everyday. Participant is engaged in fifteen unimanual tasks during the three-week training that provides them sufficient challenge and opportunities for repetition.~SR is incorporated on the 1-hour structured practice by using video playback to help participants realize their own performance for better learning. Participant first performs a task with videotaping, then identifies steps with problems or difficulties by video playback of participant's performance. Secondly, participant is asked for possible solutions, prompting is given if needed. Lastly, participant performs the activity by adopting the suggested solutions with videotaping again to facilitate participant's evaluation of new performance.
Study NCT02957708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: A combination of training on functional and remedial activities on unimanual tasks and bimanual tasks that based primarily on neurodevelopmental approach are provided. The training aims at increasing control, strength and functional use of their affected arm and hand, and improving bimanual coordination in performing daily activities. Each participant receives 1 to 2 hours of training per week at school. Home exercise including both unimanual and bimanual tasks is prescribed to them as well.
Study NCT02952716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human cord blood mononuclear cell
Description: The patients were treated by human cord blood mononuclear cell through subarachnoid space
Study NCT02952716 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: hyperbaric oxygen
Description: The patients were treated by hyperbaric oxygen
Study NCT02952716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen
Description: The patients were treated by hyperbaric oxygen
Study NCT02143245 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Open Tissue Biopsy
Description: During the standard of care revision surgery, 6 to 8 small tissue samples will be taken in order to test for infection. This is standard of care treatment. As part of this study, an additional 1 to 2 samples of tissue would be taken in order to develop a test to determine more precisely what type of infection there may be.
Study NCT00628810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00628810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00628810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00628810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00634673 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sandwich
Description: standard meal:sandwich (7.23 kcal/kg-total energy; 43.35% fat, 21.95% protein, and 34.70% carbohydrate)
Study NCT01281891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIA
Description: Ropivacaine 0.2% Ketorolac 30 mg Adrenaline 0.1 mg/ml
Study NCT01281891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I/T morphine
Description: Morphine special 0.1 mg injected intrathecally
Study NCT02424149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine
Study NCT02838160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine Care
Description: After baseline measurement, Group 1 did not receive any intervention or education.
Study NCT02838160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine care Plus the designed booklet
Description: Group 2 received only the designed booklet without any participation in the oral presentation.
Study NCT02838160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine care Plus the designed booklet Plus participation in oral presentations
Description: Group 3 participated in oral presentations 14 days after completing self-study booklet. Interactive, standardized and mandatory oral presentations were held five times to ensure maximum attendance of the three nursing shifts.
Study NCT02838160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine care Plus the designed booklet Plus participation in oral presentations Plus clinical teaching in bedside
Description: The Group 4 received clinical teaching in bedside after completing self-study booklet and a series of interactive, standardized and mandatory 90-120-minute oral presentations.
Study NCT03306030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Split dose of 4L PEG
Description: All patients were given oral instruction for bowel preparation on the day of appointment and re-instruction through phone call on two days before scheduled colonoscopy. They were instructed to have a regular lunch and take only clear liquid or low-residual food for the dinner on the day before colonoscopy. The participants began to drink the first 2 L of PEG at 7:00-9 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.